| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17161 R71973 |
Vaclavik - Amlodipine, 2024 | Preterm delivery | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 3.25 [2.58;4.09] | -/90 -/71,860 | - | 90 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17153 R71941 |
Al Khalaf - Calcium channel blockers (Controls unexposed, disease free), 2022 | Preterm birth (less than 37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.95 [2.01;4.33] C excluded (control group) |
29/289 63,460/1,739,944 | 63,489 | 289 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17150 R71920 |
Al Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 | Preterm birth (less than 37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 2.20 [1.61;3.02] C | 50/289 677/7,809 | 727 | 289 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13513 R52198 |
Fitton - Calcium blockers (Controls unexposed, disease free), 2020 | Preterm birth (birth on or before 36 weeks gestation). | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
4.73 [2.90;7.71] excluded (control group) |
39/167 12,622/250,693 | 12,661 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14422 R57250 |
Fitton - Calcium blockers (Controls unexposed, sick), 2020 | Preterm birth (birth on or before 36 weeks gestation) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 3.00 [2.08;4.32] C | 39/167 736/7,971 | 775 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13387 R52258 |
Mito - Amlodipine, 2019 | Preterm birth (<37 wks) | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 0.56 [0.26;1.24] C | 10/48 41/129 | 51 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13449 R51810 |
Su - Calcium blockers (Controls unexposed, disease free), 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.66 [1.92;3.67] C excluded (control group) |
47/303 529/8,181 | 576 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13443 R51792 |
Su - Calcium blockers (Controls unexposed, sick), 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 2.11 [1.43;3.10] | 47/303 84/1,006 | 131 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13987 R54924 |
Weber-Schoendorfer - Calcium blockers, 2008 | Preterm children (<37 weeks) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 4.63 [2.94;7.27] | 54/227 47/722 | 101 | 227 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13988 R54961 |
Magee - Calcium blockers, 1996 | Delivery < 37 weeks | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 4.01 [1.03;15.62] | 18/64 6/71 | 24 | 64 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 2.50 [1.79;3.51] | 1,809 | 1,188 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = 0.4466 (by Egger's regression)
slope=1.2952 (0.3778); intercept=-1.6355 (1.9808); t=0.8257; p=0.4466
excluded 13449, 13513, 17153